Correction to: Diabetologia

DOI: https://doi.org/10.1007/s00125-017-4479-9

The baseline insulin data given in Table 1 for the placebo group were incorrectly reported as 51 ± 10 pmol/l instead of 48 ± 10 pmol/l. This mistake also impacts on data reported in Table 4. The authors also note an error in the reported change in noradrenaline levels, from pre- to post-pioglitazone treatment (Table 4). The relevant rows from Tables 1 and 4 are reproduced here, with corrected data shown in bold. These corrections do not change the statistical significance of any comparison.

Table 1  Participant baseline characteristics
Table 4  Basal, fasting hormones, metabolites and lipids before and after the intervention